uMotif Competitive Intelligence & Landscape

uMotif (umotif.com) is a leading provider of modern eCOA/ePRO (electronic Clinical Outcome Assessment / electronic Patient-Reported Outcome) and eConsent platforms, empowering clinical and real-world research. Founded in 2012, uMotif emerged from the insight gained from working with Parkinson's patients and other therapy areas, aiming to provide digital tools for better health management and communication with clinicians [umotif.com/our-story/]. The company focuses on a patient-centric approach, which it considers the bedrock of modern eCOA systems, ensuring a superior participant experience and exceptional data capture to drive high compliance, engagement, and retention while reducing dropouts [umotif.com/].

uMotif offers an all-in-one, cloud-native eCOA platform that is highly configurable and scalable, designed to adapt quickly to protocol-specific requirements. Beyond its core eCOA solution, uMotif provides a suite of tools including eConsent/Consent Management, Trial Awareness, Patient Ride with Uber Health, and Site Productivity solutions. These offerings aim to strengthen the patient-site relationship, which is crucial for improving eCOA compliance and retention in studies across all phases and indications [umotif.com/]. The platform is GCP, 21 CFR Part 11, and GDPR-compliant, with cloud hosting in the US, Europe, and China, supporting global and scalable operations [umotif.com/].

The target market for uMotif includes sponsors and Contract Research Organizations (CROs) conducting clinical and real-world studies, aiming to enhance data quality and study efficiency [umotif.com/ecoa/].

uMotif's solutions are engineered to achieve high compliance rates, often exceeding 90%, in both clinical and real-world studies by engaging every participant with configurable experiences [umotif.com/patient-engagement/]. With leadership boasting decades of experience in clinical trials, site operations, technology, and patient engagement [umotif.com/], uMotif is committed to high-touch support and adaptability, ensuring studies are completed on scope, on time, and with the highest quality [umotif.com/].

uMotif (umotif.com) specializes in providing a modern eCOA/ePRO and eConsent platform for clinical and real-world research. Their core offerings are centered around patient centricity, aiming to enhance participant engagement, compliance, and data quality in clinical trials. The company's platform integrates electronic Clinical Outcome Assessments (eCOA), electronic Patient-Reported Outcomes (ePRO), and eConsent solutions to streamline data capture and management across all trial phases, from Phase I to III.

uMotif distinguishes itself by moving beyond simple digitization of paper forms, offering a highly configurable and scalable cloud-native solution designed for an intuitive user experience and integration with wearables and real-world data.

While uMotif clearly outlines its diverse range of solutions, including eCOA, eConsent, Patient Engagement, and Scientific Consulting services, specific pricing plans, tiers, or a breakdown of free versus paid features are not publicly disclosed on their website. The company emphasizes a **

uMotif actively seeks to expand its team, reflecting its position as one of the fastest-growing companies in the clinical trial technology market. The company consistently posts job openings on its careers page, inviting individuals who are passionate about innovative technology and making a real difference in patients' lives. This open approach to hiring signals a strong growth trajectory and a continuous investment in talent across various departments.

Recent hiring trends at uMotif indicate a strategic focus on bolstering its leadership and commercial capabilities. Notable appointments include Andrea Valente as Chief Executive Officer in June 2026, bringing strategic leadership and deep domain expertise to guide the company's advancement in modern clinical trial technologies [Source: https://umotif.com/news/umotif-announces-andrea-valente-is-chief-executive-officer/]. Additionally, James Thatcher was appointed Chief Commercial Officer in May 2026, leveraging his eClinical expertise and proven record of commercial growth [Source: https://umotif.com/news/umotif-appoints-james-thatcher-chief-commercial-officer/]. These high-profile hires, along with the appointment of Florence Mowlem, PhD, as Chief Scientific Officer, underscore uMotif's commitment to expanding its market presence and scientific leadership [Source: https://umotif.com/news/umotif-names-florence-mowlem-phd-chief-scientific-officer/].

Further reinforcing its expansion, uMotif significantly grew its leadership team in July 2022 to support ambitious growth strategies in both the US and European markets [Source: https://umotif.com/news/umotif-expands-leadership-team-to-support-growth-in-us-and-eu-markets/]. Key additions like John Barron as Chief Technology Officer and Julia Lakeland as Chief Customer Success Officer, both with extensive experience in clinical trial solutions, demonstrate uMotif's dedication to enhancing its robust platform and ensuring exceptional customer outcomes [Source: https://umotif.com/leadership-team/john-barron/] [Source: https://umotif.com/leadership-team/julia-lakeland/]. This consistent pattern of strategic hires across leadership, commercial, scientific, and technical roles indicates a company in a significant growth phase, rather than experiencing layoffs, signaling confidence in its eCOA/ePRO and eConsent platform's market demand and future potential.

uMotif, a company specializing in patient-centric data capture for clinical research, has demonstrated consistent financial growth and successful fundraising efforts. The company secured a significant investment of $25.5 million from a fund managed by Athyrium Capital Management, LP, to further scale its patient-first software platform. This funding builds upon earlier investments from existing partners AlbionVC and DNV, underscoring investor confidence in uMotif's market position and growth potential [umotif.com/news/25-5mofnewinvestmentfromafundmanagedbyathyriumcapitalmanagement/].

Prior to the Athyrium Capital Management investment, uMotif completed a Series A funding round, raising £5 million. This round was led by AlbionVC, an existing investor, with additional participation from DNV GL and angel investors. The Series A funding was earmarked to accelerate uMotif's expansion into new study types and high-demand territories, fueling the development of its patient-centric and decentralized approach to clinical studies [umotif.com/news/umotif-raise-5-million-to-power-decentralised-clinical-trials-and-get-therapies-to-patients-faster/]. Earlier, in June 2018, uMotif had secured £2.4 million in funding, led by Albion Capital and supported by several angel investors, to further develop its software platform for capturing real-world data [umotif.com/news/umotif-secures-2-4-million-funding-led-by-albion-capital/].

uMotif has consistently reported strong financial performance, completing record growth years. In 2025, the company saw increased year-over-year bookings, expanded its customer base, and boosted contract values, showcasing its market leadership in clinical trial patient data collection [umotif.com/news/umotif-earns-market-accolades-for-ecoa-platform-demonstrates-industry-leadership-in-2025/]. The company's innovative eCOA/ePRO platform, designed to be patient-centric and modern, has been a key driver of this growth, positioning uMotif as a fast-growing entity within the clinical research technology market [umotif.com/news/umotif-completes-record-growth-year/]. The appointment of Gary Parrott as Chief Financial Officer in October 2021, bringing two decades of life sciences financial experience, further strengthened uMotif's financial operations for continued expansion in the US and EU markets [umotif.com/news/umotif-expands-leadership-team-to-support-growth-in-us-and-eu-markets/].

uMotif actively participates in and hosts a variety of industry events, demonstrating its commitment to advancing clinical research through its modern eCOA/ePRO and eConsent platforms. The company regularly showcases its solutions at major conferences and trade shows, providing opportunities for engagement with industry professionals. For example, uMotif is a consistent presence at events like OCT Europe and OCT East Coast, which bring together leaders in clinical operations, data management, AI, innovation, and technology [umotif.com/events/].

uMotif's executives, including CEO Steve Rosenberg, Chief Patient Officer Bruce Hellman, Chief Scientific Officer Florence Mowlem PhD, and Chief Operating Officer Andrea Valente, frequently share their expertise and insights at these gatherings. They focus on how uMotif's technology innovation strengthens the patient-site relationship and improves clinical trial outcomes. The company plans to sponsor, exhibit, and speak at numerous prominent industry events in 2025, including the SCOPE Summit for Clinical Op Executives, the 18th Annual Outsourcing in Clinical Trials West Coast, Clinical Outsourcing Group UK, acdm26, and Clinical Outsourcing Group Nordics [umotif.com/news/umotif-earns-market-accolades-for-ecoa-platform-demonstrates-industry-leadership-in-2025/]. This robust participation ensures that uMotif remains at the forefront of industry discussions and technological advancements.

Beyond in-person conferences, uMotif extends its reach through webinars and thought leadership initiatives. They have hosted webcasts on critical topics such as unifying eConsent, ePRO, and eCOA to elevate participant experience in global clinical trials [umotif.com/news/umotif-and-clinone-unify-ecoa-epro-and-econsent-to-improve-the-participant-experience-and-endpoint-data-quality-in-global-clinical-trials/]. Additionally, uMotif leverages its blog and podcast platforms to share insights, including executive takeaways from conferences like the Society for Clinical Data Managers (SCDM) Conference, where discussions around patient-centricity and AI in clinical research are prominent [umotif.com/blogs/]. Through these varied event participations and resources, uMotif reinforces its role as a leader in patient-centric eClinical solutions.